Proteomics International (ASX:PIQ) has landed a national distribution deal and US Medicare reimbursement pricing for its diabetic kidney disease test, PromarkerD, at almost the same moment it has disclosed a cash position covering only around 1.7 quarters of funding, making the next few months a genuine test of whether commercial traction can outrun the balance sheet.

A Biomarker Diagnostics Business Built on an Accredited Lab

Proteomics International operates a Perth-based analytical laboratory accredited to ISO 15189 and ISO 17025 standards, alongside a portfolio of proprietary protein biomarker tests. Its lead product, PromarkerD, is a prognostic blood test that predicts the risk of diabetes-related chronic kidney disease up to four years in advance, with reported sensitivity of 76 to 85 per cent and specificity of 92 to 95 per cent. The company also has PromarkerEso, targeting oesophageal cancer risk, and PromarkerEndo, targeting endometriosis diagnosis, the latter having received a US Patent in July 2026 extending protection to March 2041.

Distribution and Reimbursement Wins

Proteomics International signed an initial three-year Australian distribution agreement with Healius for its Promarker test portfolio in July 2026. The agreement gives access to a pathology network of more than 2,000 collection centres, while Proteomics remains responsible for testing and reporting. US Medicare established a fee-schedule price of US$390.75 for the next-generation PromarkerD code from January 2026; payment for particular patients still depends on applicable coverage criteria.

What the Evidence Means Against a Tight Cash Position

The distribution agreement establishes an access route, but Proteomics said Revenue from it could not yet be reliably estimated. The Medicare fee-schedule price likewise does not by itself ensure broad test coverage or volume. The reported A$3.5 million cash balance at June 2026 and an estimate of 1.7 quarters of funding make subsequent financing and cash-flow disclosures relevant.

A Diagnostics Sector Where Reimbursement Is the Real Catalyst

Diagnostics companies on the ASX are increasingly judged less on test accuracy — which for PromarkerD already compares reasonably with established risk markers — and more on whether they can convert that accuracy into payer coverage and test Volume at scale. The Healius agreement and Medicare pricing both address that commercial gap directly, but the market will want to see actual test volumes and revenue growth, not just distribution and pricing agreements, before re-rating the going-concern risk.

Risks and What to Watch

The central risk is funding: with roughly two quarters of cash and a disclosed going-concern uncertainty, the company may need to raise Capital on dilutive terms if test volume growth is slower than required. Broader US Medicare coverage remains pending rather than confirmed, and management turnover — with a new CEO and CFO appointed in April 2026 — adds execution uncertainty during a critical commercial period. Laboratory-based diagnostics businesses also carry ongoing accreditation and quality-system obligations, and any lapse in those standards could disrupt test processing independently of the commercial and funding questions.

Investors should watch the next quarterly cash-flow report closely, PromarkerD test volumes under the Healius agreement, and any update on broader US reimbursement coverage.